,outcome,arm 1,arm 2
0,intervention,topotecan group,paclitaxel
0,"4 years post-randomisation, median survival",63.0 weeks ( range < 1 to 238.4+ weeks ; 20.5 % censored ),53.0 weeks ( range < 1 to 226.3+ weeks ; 12.3 % censored )
